Treatment and quality of life in patients with chronic obstructive pulmonary disease.

摘要: Treatments administered to patients with chronic obstructive pulmonary disease (COPD), especially when used in multiple combinations, are not free of interactions and side effects that can potentially impair health-related quality life (HRQL). We studied HRQL its relationship treatment a group 441 stage II or III COPD (age: 66.6 (SD: 8.3) years; FEV1: 32.4% 8.1%)) using the St George's Respiratory Questionnaire (SGRQ) 12-item short form (SF-12) Health Survey. The most prescribed drugs were ipratropium bromide (87.5%), inhaled corticosteroids (69.4%) short-acting β-2 agonists (64.9%). Patients receiving more drugs, particularly (p = 0.002) 0.031). use theophyllines was associated worse total SGRQ score (β 4.49; p < 0.001), although this negative association decreased advanced age. A trend towards scores observed high doses long-acting 3.22; 0.072). three presented than fewer 6.1, 0.001; β 7.64, 0.001, respectively). These findings suggest is scores. effect their dosages associations other on merit further research.